Use of remimazolam for pediatric sedation
EP4757802A2Pending Publication Date: 2026-06-17EAGLE PHARMACEUTICALS INC +1
Patent Information
- Authority / Receiving Office
- EP · EP
- Patent Type
- Applications
- Current Assignee / Owner
- EAGLE PHARMACEUTICALS INC
- Filing Date
- 2024-08-09
- Publication Date
- 2026-06-17
AI Technical Summary
Technical Problem
There is a need for safe and effective sedation methods for pediatric patients undergoing procedures, as existing sedatives like propofol and dexmedetomidine have safety disadvantages and their use in pediatric patients is not well established.
Method used
The use of remimazolam, an ultra-short-acting benzodiazepine, for intravenous sedation in pediatric patients, with specific dosing regimens and monitoring protocols to ensure safety and efficacy.
Benefits of technology
Remimazolam provides effective and rapid sedation with predictable recovery times, reducing the risk of adverse events such as airway obstruction and cardiovascular depression, while allowing for deeper sedation necessary for pediatric procedures.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure US2024041709_20022025_PF_FP_ABST
Abstract
The application is directed to methods of sedating a pediatric subject by administering intravenously to the subject remimazolam, or a pharmaceutically acceptable salt thereof.
Need to check novelty before this filing date? Find Prior Art